OBJECTIVE. Several clinical studies have shown the efficacy of ¹⁷⁷Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on ¹⁷⁷Lu-PSMA RLT for mCRPC across all studies published to date. CONCLUSION. The results of the systematic review and meta-analysis suggest that ¹⁷⁷Lu-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of ¹⁷⁷Lu-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: